Open AccessSerum cyfra21-1 as a biomarker in patients with nonsmall cell lung cancer
Author(s) -
Hu Zhao,
Xuejun Shi,
Zhibin Wang,
Zhengang Chen,
Guangshun Wang
Publication year - 2014
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.145878
Subject(s) - medicine , biomarker , lung cancer , confidence interval , cytokeratin , oncology , serology , receiver operating characteristic , retrospective cohort study , gastroenterology , immunology , immunohistochemistry , antibody , biochemistry , chemistry
The purpose of this retrospective study was to evaluate the clinical value of serum cytokeratin-19-fragment (cyfra21-1) as a biomarker in nonsmall cell lung cancer (NSCLC).